Oppenheimer Maintains Outperform on Cartesian Therapeutics, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler maintains an Outperform rating on Cartesian Therapeutics (NASDAQ:RNAC) with a $50 price target.
June 14, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Matthew Biegler maintains an Outperform rating on Cartesian Therapeutics with a $50 price target.
The reaffirmation of an Outperform rating and a $50 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100